Silexion Therapeutics Corp (NASDAQ: SLXN) is a clinical-stage biopharmaceutical company developing RNA interference therapies targeting KRAS-driven cancers, with an initial focus on locally advanced pancreatic cancer (LAPC). The company generates no product revenue as of the fiscal year ended December 31, 2025, having financed operations through equity securities sales and royalty-bearing grants from Israel's Innovation Authority (IIA). Silexion completed a business combination with Moringa Acquisition Corp on August 15, 2024, after which its ordinary shares and warrants began trading on the Nasdaq Global Market under the symbols SLXN and SLXNW. The company's pipeline centers on SIL204, a second-generation siRNA product candidate, with toxicology studies completed in 2025 and a regulatory submission targeting a Phase 2/3 trial made in Q1 2026. General and administrative expenses totaled $4.5 million for FY2025, down from $6.8 million in FY2024. An At The Market Offering Agreement with H.C. Wainwright, dated September 26, 2025, provides for the sale of up to $13,170,000 of ordinary shares.

Revenue model

No product revenue. Operations financed through equity issuances, including public offerings in January 2025 and September 2025, an ATM facility with H.C. Wainwright of up to $13,170,000, and royalty-bearing grants from Israel's Innovation Authority. A convertible promissory note issued to the Moringa sponsor had $1,633,000 outstanding as of the filing date (March 17, 2026).

Products and services

SIL204: a second-generation siRNA product candidate targeting KRAS mutations, in pre-Phase 2/3 development for locally advanced pancreatic cancer (LAPC) as of Q1 2026. Loder: a first-generation siRNA product that completed a Phase 2 trial in LAPC patients, serving as validation of the siRNA delivery approach. Preclinical pipeline targets additional oncological indications harboring the KRASG12 mutation, with CTG assay results in 2025 showing high inhibition activity.

Customers and end markets

End market is KRAS-mutant cancer patients, initially those with locally advanced pancreatic cancer. No commercial customers as of FY2025. Patient population size is not yet precisely determined; the company notes its patient identification efforts are in early stages.

Value-chain role

Drug developer at the preclinical and early clinical stage. Relies on contract research organizations (CROs) for clinical and preclinical study execution. No manufacturing or commercialization operations as of FY2025.

Geographic exposure

Incorporated in the Cayman Islands with operational roots through Silexion Israel, an Israeli subsidiary. Listed on the Nasdaq Global Market. No commercial geographic revenue mix disclosed given pre-revenue status.

Source: SEC 10-K, filed 2026-03-17

Industry: Biological Products, (No Diagnostic Substances)